2022, Hong et al. 2025), and given a recent report showing a strategy to target EV‐carried CD73 effects in other tumour types using a bispecific antibody toward CD73xEpCAM (Ploeg et al. 2021), it would also be interesting to evaluate this effect in the context of osimertinib resistance. The gene discussed is NT5E; the disease is neoplasm.